Press Centre
Press Releases
Phynova Exhibits at the UK´s Top Small and Mid Cap Private Investor Show
Phynova Group plc
("Phynova" or "the Company")
Phynova Exhibits at the UK´s Top Small and Mid Cap Private Investor Show
Phynova Group plc (AIM: PYN), the developer of prescription pharmaceuticals derived from Chinese botanical medicines, today announces that it will be exhibiting on stand 32 at the Growth Company Investor Show 2007, the country´s leading investment exhibition, on Wednesday 13 June at the Barbican Centre, Silk Street, London EC2Y 8DS.
The event is designed to showcase small- and mid-cap quoted companies to private and professional investors. Leading figures from the business and media worlds will be talking about their own experiences in the investment world.
Representing Phynova at the Barbican will be Robert Miller, Phynova´s CEO, along with Tony Mills, Business Development Director, Sarah Wadham, Investor Relations, and Alice Lyon, Executive Assistant. Phynova´s team will be ready to describe the progress in Phynova´s drug development pipeline and to highlight the investment growth potential awaiting new investors.
- Ends -
For further information, please contact:
Phynova Group PLC 07775 920 963
Robert Miller, Chief Executive Officer www.phynova.com
Nominated Adviser:
Nabarro Wells & Co. Limited 020 7710 7400
Marc Cramsie/John Wilkes
Broker:
J M Finn & Co. Limited 020 7628 9688
Sam Smith
Media enquiries:
Abchurch Communications 020 7398 7700
Peter Laing/Ashley Tapp/Stephanie Cuthbert
Stephanie.cuthbert@abchurch-group.com
www.abchurch-group.com
Notes to editors:
About Phynova
Phynova is a UK company developing prescription pharmaceuticals derived from Chinese botanical medicines. Phynova is focused on viral and metabolic diseases and cancer. Phynova´s lead product for hepatitis C will enter Phase II trials in the first half of this year. Two further products, in fatty liver disease and post operative ileus are targeted for entry to the clinic in 2007 and there are a further four products in preclinical development.
About Hepatitis C and Phynova´s clinical candidate PYN17
Hepatitis C is a liver disease caused by the hepatitis C virus ("HCV"). Hepatitis C is usually transmitted by injections of illicit drugs, or through exposure to contaminated blood or blood products. Symptoms include fatigue, abdominal discomfort or tenderness, muscle and joint pain, nausea and loss of appetite. Symptoms may persist in patients, even after viral clearance following interferon-ribavirin therapy. Chronic hepatitis C can result in cirrhosis of the liver, which can lead to liver failure and other serious complications, and liver cancer.
Hepatitis C affects over 200 million people world wide, including over four million people in the US. Currently available treatments with pegylated interferon and ribavirin are only effective in approximately 50% of patients treated, often with significant associated toxicity and side effects. The market for treatments for hepatitis C is estimated to be US$9 billion by 2010.
Phynova believes that PYN17 is the only drug in clinical development specifically designed to treat the debilitating symptoms of chronic hepatitis C. It is based on a novel formulation of four plant extracts that have a long history of safe and efficacious use in the treatment of liver ailments in Asia and the West.
About the Growth Company Investor Show
The Growth Company investor Show provides an opportunity for investors and companies to meet face to face and the conference aims to attract up to 2,000 professional and private investors. Running alongside the show there will be a conference of seminars and speakers. The show is free to attend.
For further information please visit www.phynova.com;
www.GrowthCompanyInvestorShow.co.uk
11/06/2007
<< Back | See all current Press releses